Eli Lilly's Q1 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure. CBS News: Popular diabetes medication Mounjaro will be in short supply through April FiercePharma: Eli Lilly's popular diabetes drug Mounjaro to face continued supply squeeze through April, FDA says Amid steadily increasing demand for Eli Lilly’s popular diabetes med Mounjaro, it appears patients on multiple dose strengths may have to wait even longer than anticipated to re-up on supply. The FDA ...
Eli Lilly's popular diabetes drug Mounjaro to face continued supply squeeze through April, FDA says Yahoo: Some doses of Lilly's Mounjaro in tight supply through April, US FDA says Some doses of Lilly's Mounjaro in tight supply through April, US FDA says Yahoo: Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA says Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA says CNBC: Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says Most doses of Eli Lilly's highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year due to increased demand, according ... Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says The popular weight-loss and diabetes medication tirzepatide is no longer in short supply, the Food and Drug Administration said. Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro ...
